Gratus Capital’s Zymeworks ZYME Stock Holding History

Gratus Capital’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,000	Closed	-$466K	–	192
2020 Q3	$466K	Hold	10,000	–	–	0.07%	122
2020 Q2	$361K	Hold	10,000	–	–	0.06%	130
2020 Q1	$355K	Buy	+10,000	New	+$409K	0.07%	132

Other funds holding ZYME

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Gratus Capital's ZYME Position: Q4 2020 in Review

Gratus Capital sold out of Zymeworks (ZYME) in Q4 2020, closing a stake of 10,000 shares — an estimated $466K sold.

Gratus Capital first reported a position in ZYME in Q1 2020 and held it in 3 quarters. The position peaked at $466K in Q3 2020. 138 funds tracked by Wall St. Rank hold ZYME as of Q4 2020.

Gratus Capital reported no remaining Zymeworks position as of Q4 2020 after selling out during the quarter.
Gratus Capital sold 10,000 Zymeworks shares in Q4 2020, an estimated $466K.
Gratus Capital first reported a position in Zymeworks in Q1 2020 and held it in 3 quarters.
Gratus Capital's Zymeworks position peaked at $466K in Q3 2020.
138 funds tracked by Wall St. Rank held Zymeworks as of Q4 2020.

Based on Gratus Capital's 13F filing for Q4 2020, filed 3 Feb 2021.